AbCellera Biologics, Inc. (ABCL)

In the past six months, AbCellera Biologics Inc. stock decreased by 34.79% as of December 2025, but was up 40% in the past quarter and nearly 40% year-to-date as of September 2025. Key events include a Q3 2025 earnings report on November 6, 2025, where the company reported a loss but topped revenue estimates, and the announcement of full-year 2025 financial results on February 24, 2026, reporting $75.1 million in total revenue and a net loss of $146.4 million, while exceeding analysts' EPS expectations for Q4 2025. Clinical trial progress, such as ABCL575 entering Phase 1 and ABCL635 entering Phase 2, contributed to stock momentum. As of March 2026, AbCellera has a consensus rating of 'Hold' from analysts.

Demand seasonality for AbCellera Biologics Inc. is not directly comparable to consumer goods. Demand is primarily driven by clinical trial success, partnerships and collaborations, unmet medical needs and disease outbreaks, and research and development cycles. The business is tied to the cyclical nature of drug development, scientific breakthroughs, and strategic collaborations rather than seasonal consumer patterns.

AbCellera Biologics Inc. is a clinical-stage biotechnology company based in Vancouver, Canada, specializing in antibody therapeutics discovery and development. It operates in the Pharmaceuticals & Biotech sector and Life Sciences Tools and Services industry, utilizing an integrated technology platform for antibody-based medicines across various therapeutic areas. Key products include ABCL635 (Phase 2 for vasomotor symptoms), ABCL575 (Phase 1 for atopic dermatitis), ABCL688 (IND-enabling studies for autoimmunity in Q2 2025), ABCL386 (oncology), and COVID-19 treatments like Bamlanivimab (Emergency Use Authorization revoked in April 2021). The company collaborates with pharmaceutical firms like Eli Lilly, AbbVie, and Biogen.

AbCellera Biologics Inc. is headquartered in Vancouver, British Columbia, Canada, with additional offices and facilities in Montreal, Canada; California, New York, and Boston, United States; Sydney, Australia; and Cambridge, United Kingdom.

AbCellera's brand reputation is shaped by its technological advancements in antibody discovery and contributions to global health, particularly its role in the Pandemic Prevention Platform and development of Bamlanivimab for COVID-19. The company has continued to build its reputation as it transitioned to a clinical-stage biotech company. The advancement of its internal pipeline programs, such as ABCL635 and ABCL575, into clinical trials, has been a positive development. Integrated clinical manufacturing capabilities, expected to be completed by the end of 2025, are also anticipated to enhance operational efficiency.

AbCellera Biologics Inc. has a diverse ownership structure, with approximately 29.63% to 36.19% held by institutional investors, 41.17% to 44.36% by insiders, and 19.88% to 34.38% by retail investors. Major institutional owners include Baker Bros. Advisors Lp and Capital World Investors. Key individual owners include Carl L. G. Hansen (CEO and founder) and Thermopylae Holdings Ltd.